140 related articles for article (PubMed ID: 10398086)
1. Immunostaining for vasostatin I distinguishes between ileal and lung carcinoids.
Cunningham RT; Pogue KM; Curry WJ; Johnston CF; Sloan JM; Buchanan KD
J Pathol; 1999 Feb; 187(3):321-5. PubMed ID: 10398086
[TBL] [Abstract][Full Text] [Related]
2. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A as a determinant of midgut carcinoid tumour volume.
Kölby L; Bernhardt P; Swärd C; Johanson V; Ahlman H; Forssell-Aronsson E; Stridsberg M; Wängberg B; Nilsson O
Regul Pept; 2004 Aug; 120(1-3):269-73. PubMed ID: 15177946
[TBL] [Abstract][Full Text] [Related]
4. Different patterns of chromogranin A and Leu-7 (CD57) expression in gastrointestinal carcinoids: immunohistochemical and confocal laser scanning microscopy study.
Jirásek T; Hozák P; Mandys V
Neoplasma; 2003; 50(1):1-7. PubMed ID: 12687271
[TBL] [Abstract][Full Text] [Related]
5. Secretoneurin in carcinoids of the appendix-immunohistochemical comparison with chromogranins A,B and secretogranin II.
Prommegger R; Obrist P; Ensinger C; Schwelberger HG; Wolf C; Fischer-Colbrie R; Mikuz G; Bodner E
Anticancer Res; 1998; 18(6A):3999-4002. PubMed ID: 9891437
[TBL] [Abstract][Full Text] [Related]
6. High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids.
Andersson E; Swärd C; Stenman G; Ahlman H; Nilsson O
Endocr Relat Cancer; 2009 Sep; 16(3):953-66. PubMed ID: 19458023
[TBL] [Abstract][Full Text] [Related]
7. The expression of selected neuroendocrine markers and of anti-neoplastic cytokines (IL-2 and IL-12) in lung cancers.
Kasprzak A; Przewoźna M; Surdyk-Zasada J; Zabel M
Folia Morphol (Warsz); 2003 Nov; 62(4):497-9. PubMed ID: 14655151
[TBL] [Abstract][Full Text] [Related]
8. Tumour markers in neuroendocrine tumours.
Oberg K; Janson ET; Eriksson B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S160-2. PubMed ID: 10604122
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors.
Srivastava A; Hornick JL
Am J Surg Pathol; 2009 Apr; 33(4):626-32. PubMed ID: 19065104
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids.
Srivastava A; Padilla O; Fischer-Colbrie R; Tischler AS; Dayal Y
Am J Surg Pathol; 2004 Oct; 28(10):1371-8. PubMed ID: 15371954
[TBL] [Abstract][Full Text] [Related]
12. Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors.
Conlon JM
Regul Pept; 2010 Nov; 165(1):5-11. PubMed ID: 19931574
[TBL] [Abstract][Full Text] [Related]
13. [Incidental endoscopic finding--ileum carcinoid. Treatment strategy and prognostic factors].
Hoffmann TF; Beer M; Burlefinger R; Günther B
Chirurg; 1995 Jan; 66(1):62-5. PubMed ID: 7889794
[TBL] [Abstract][Full Text] [Related]
14. [New diagnostic method in pulmonary carcinoid].
Csiszér E; Antus B; Himber G; Hertel K; Fillinger J
Magy Onkol; 2007; 51(3):225-8. PubMed ID: 17922062
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical distribution of chromogranins A and B and secretogranin II in neuroendocrine tumours of the gastrointestinal tract.
Fahrenkamp AG; Wibbeke C; Winde G; Ofner D; Böcker W; Fischer-Colbrie R; Schmid KW
Virchows Arch; 1995; 426(4):361-7. PubMed ID: 7599788
[TBL] [Abstract][Full Text] [Related]
16. Catestatin--a novel neuropeptide in carcinoid tumors of the appendix.
Prommegger R; Ensinger C; Adlassnig C; Vaingankar S; Mahata SK; Marksteiner J; Margreiter R
Anticancer Res; 2004; 24(1):311-6. PubMed ID: 15015613
[TBL] [Abstract][Full Text] [Related]
17. Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis.
Cunningham JL; Grimelius L; Sundin A; Agarwal S; Janson ET
Acta Oncol; 2007; 46(6):747-56. PubMed ID: 17653896
[TBL] [Abstract][Full Text] [Related]
18. Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours.
Kasprzak A; Olejniczak K; Przybyszewska W; Zabel M
Folia Morphol (Warsz); 2007 Aug; 66(3):159-66. PubMed ID: 17985312
[TBL] [Abstract][Full Text] [Related]
19. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival.
Voland P; Besig S; Rad R; Braun T; Baur DM; Perren A; Langer R; Höfler H; Prinz C
Neuroendocrinology; 2009; 89(1):66-78. PubMed ID: 18708724
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical study of secretogranin II in 62 neuroendocrine tumours of the digestive tract and of the pancreas in comparison with other granins.
Le Gall F; Vallet VS; Thomas D; De Monti M; Duval J; Ramee MP
Pathol Res Pract; 1997; 193(3):179-85. PubMed ID: 9198103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
